Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

What is Genetic Engineering?

What is Genetic Engineering?

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Recombinant DNA

Recombinant DNA

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gene medication or genetic modification? The devil is in the details.

Nature biotechnology·2003

Same author

[Therapeutic cloning--a breakthrough without scientific evidence?].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2002

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

When gene medication is also genetic modification--regulating DNA treatment.

Grethe S Foss¹, Sissel Rogne

¹The Norwegian Biotechnology Advisory Board, P.O. Box 522 Sentrum, NO-0105 Oslo, Norway. grethe.foss@bion.no

|June 5, 2007

Summary

DNA vaccination and gene therapy involve genetic modification. Norway regulates DNA-vaccinated animals as genetically modified, posing challenges. This paper explores regulatory solutions for DNA-based interventions.

More Related Videos

In vivo Application of the REMOTE-control System for the Manipulation of Endogenous Gene Expression

In vivo Application of the REMOTE-control System for the Manipulation of Endogenous Gene Expression

Published on: March 29, 2019

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Related Experiment Videos

Last Updated: Jul 14, 2026

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

In vivo Application of the REMOTE-control System for the Manipulation of Endogenous Gene Expression

In vivo Application of the REMOTE-control System for the Manipulation of Endogenous Gene Expression

Published on: March 29, 2019

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Area of Science:

Biotechnology
Regulatory Science
Genetics

Background:

Molecular methods in DNA vaccination and gene therapy overlap with genetic modification techniques.
Regulatory frameworks in some regions, including Norway, classify animals receiving DNA-based treatments as genetically modified.
This classification presents practical and regulatory challenges, and conflicts with biological understanding.

Purpose of the Study:

To examine the background of Norway's regulatory interpretation of DNA-vaccinated animals.
To discuss the complexities arising from overlapping definitions of gene therapy, DNA vaccination, and genetic modification.
To propose potential solutions for handling these regulatory challenges.

Main Methods:

Comparative analysis of regulatory approaches to genetic modification and DNA-based therapies.
Discussion of biological distinctions and overlaps between immune responses and trait modification.
Review of existing Norwegian regulations concerning genetically modified organisms and DNA interventions.

Main Results:

The current Norwegian regulation views animals with persistent plasmid DNA as genetically modified, irrespective of therapeutic intent.
This regulatory stance creates significant practical hurdles and is biologically counter-intuitive.
The distinction between vaccination-induced immune responses and genetic modification is becoming increasingly blurred.

Conclusions:

Re-evaluating the regulatory definition of genetic modification is necessary to accommodate advancements in DNA-based technologies.
Alternative regulatory pathways are needed to effectively manage DNA vaccination and gene therapy without conflating them with traditional genetic modification.
Harmonizing regulatory approaches will facilitate the responsible development and application of these powerful biotechnologies.